These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 14173475)

  • 1. TESTING THE EFFECTIVENESS OF LIVE ADENOVIRUS VACCINE. II. IMMUNOGENIC PROPERTIES.
    SELIVANOV AA; PLESHANOVA RA; SMORODINTSEV AA
    Acta Virol; 1964 May; 8():271-6. PubMed ID: 14173475
    [No Abstract]   [Full Text] [Related]  

  • 2. TESTING THE EFFECTIVENESS OF LIVE ADENOVIRUS VACCINE. I. REACTOGENIC PROPERTIES.
    SELIVANOV AA; PLESHANOVA RA; SKRYABINA EA; SMORODINTSEV AA
    Acta Virol; 1964 May; 8():263-70. PubMed ID: 14173474
    [No Abstract]   [Full Text] [Related]  

  • 3. II. EFFICACY OF ADJUVANT AND AQUEOUS ADENOVIRUS VACCINES IN PREVENTION OF NAVAL RECRUIT RESPIRATORY DISEASE.
    MILLER LF; PECKINPAUGH RO; ARLANDER TR; PIERCE WE; EDWARDS EA; DEBERRY P; PHILLIPS IA; ROSENBAUM MJ
    Am J Public Health Nations Health; 1965 Jan; 55(1):47-59. PubMed ID: 14246107
    [No Abstract]   [Full Text] [Related]  

  • 4. DOSAGES OF VARIOUS TRIVALENT AND MONOVALENT ADENOVIRUS VACCINES IN THE PROPHLAXIS OF ACUTE RESPIRATORY ILLNESS.
    STILLE WT; HANTOVER MJ
    Am J Hyg; 1964 Jul; 80():121-34. PubMed ID: 14192764
    [No Abstract]   [Full Text] [Related]  

  • 5. A long-term study of antibody response to an adenovirus vaccine and observations on the effect of concurrent adenovirus disease.
    CULVER JO; LENNETTE EH; FOX VL; FLINTJER JD
    Am J Hyg; 1959 Jan; 69(1):38-48. PubMed ID: 13626943
    [No Abstract]   [Full Text] [Related]  

  • 6. COMPARATIVE EFFECTIVENESS OF 1/2 ML AND 1 ML DOSES OF ADENOVIRUS VACCINE ON RESPIRATORY DISEASE IN NAVY RECRUITS. RES PROJ REP MR 005.09-1203-1.
    PIERCE WE; MILLER LF
    Rep U S Nav Med Res Lab; 1963 Sep; 13():1-11. PubMed ID: 24547139
    [No Abstract]   [Full Text] [Related]  

  • 7. Simultaneous oral administration of live adenovirus types 4 and 7 vaccines. Protection and lack of emergence of other types.
    Gooch WM; Mogabgab WJ
    Arch Environ Health; 1972 Dec; 25(6):388-94. PubMed ID: 4343867
    [No Abstract]   [Full Text] [Related]  

  • 8. Studies of the significance of the recall phenomenon in the antibody response to adenovirus vaccine and infection.
    van der VEEN ; PRINS A
    J Immunol; 1960 Jun; 84():562-8. PubMed ID: 13841541
    [No Abstract]   [Full Text] [Related]  

  • 9. Adenovirus vaccine: evaluation of antibody response and protective efficacy and comparison with an earlier preparation.
    LENNETTE EH; FLINTJER JD; CULVER JO; FOX VL; STEVENS TE
    Am J Hyg; 1960 Mar; 71():193-203. PubMed ID: 14415712
    [No Abstract]   [Full Text] [Related]  

  • 10. Characteristics of vaccine-induced and natural infection with adenovirus type 4 in naval recruits.
    Rosenbaum MJ; De Berry P; Sullivan EJ; Edwards EA; Pierce WE; Muldoon RL; Jackson GG; Peckinpaugh RO
    Am J Epidemiol; 1968 Jul; 88(1):45-54. PubMed ID: 4298479
    [No Abstract]   [Full Text] [Related]  

  • 11. INFECTION WITH ADENOVIRUS TYPE 12.
    PEREIRA MS; MACCALLUM FO
    Lancet; 1964 Jan; 1(7326):198-9. PubMed ID: 14074502
    [No Abstract]   [Full Text] [Related]  

  • 12. An adenovirus vaccine potency test.
    TINT H; STONE J
    J Immunol; 1961 Mar; 86():253-6. PubMed ID: 13776999
    [No Abstract]   [Full Text] [Related]  

  • 13. [Results of immunization of volunteers with live attenuated adenovirus vaccine type IV, V and VII. (Preliminary communication)].
    SMORODINTSEV AA; SELIVANOV AA
    Vopr Virusol; 1959; 4():648-52. PubMed ID: 13832219
    [No Abstract]   [Full Text] [Related]  

  • 14. [MICROMETHOD FOR DETERMINING THE COMPLEMENT FIXATION REACTION IN THE DIAGNOSIS OF VIRAL INFLUENZA AND ADENOVIRUS DISEASES].
    ZMECHOROVSKAIA GA
    Lab Delo; 1963 Aug; 9():40-5. PubMed ID: 14083304
    [No Abstract]   [Full Text] [Related]  

  • 15. Concurrent administration of live adenovirus, type 4 and live Poliovirus, type 1 vaccines.
    Chin J; Lennette EH; Schieble JH; Magoffin RL
    Am J Epidemiol; 1968 May; 87(3):633-42. PubMed ID: 5654951
    [No Abstract]   [Full Text] [Related]  

  • 16. Antibody titer in allergic children given adenovirus vaccine.
    CHOBOT R; GOLDZIER SE; SCHWARTZ T; OSBORNE D
    J Allergy; 1959; 30(2):97-102. PubMed ID: 13630640
    [No Abstract]   [Full Text] [Related]  

  • 17. [BEHAVIOR OF COMPLEMENT-FIXING ANTIBODIES FOR ADENOVIRUS AND ECHO 6 VIRUS IN A CLOSED COMMUNITY AND IN A FREE ENVIRONMENT].
    ANGELA GC; PANIROSSI R; MARTANO M; PASQUALE A
    G Mal Infett Parassit; 1965 May; 17():256-60. PubMed ID: 14343240
    [No Abstract]   [Full Text] [Related]  

  • 18. Second field evaluation of bivalent Types 4 and 7 adenovirus vaccine.
    HILLEMAN MR; GREENBERG JH; WARFIELD MS; ANDERSON SA; GLABERE RR
    AMA Arch Intern Med; 1958 Sep; 102(3):428-36. PubMed ID: 13570730
    [No Abstract]   [Full Text] [Related]  

  • 19. Adenovirus soluble antigen vaccine studies. I. Preparation and testing of adenovirus type 5 soluble antigen vaccines.
    Metzgar DP; Thomas WJ; Insalaco CS; DeSanctis AN; Beiler JM
    Proc Soc Exp Biol Med; 1968 Jul; 128(3):679-83. PubMed ID: 5668108
    [No Abstract]   [Full Text] [Related]  

  • 20. USE OF DRIED WHOLE BLOOD COLLECTED ON FILTER PAPER DISKS IN ADENOVIRUS COMPLEMENT FIXATION AND MEASLES HEMAGGLUTINATION INHIBITION TESTS.
    BRODY JA; MCALISTER R; HASLEY R; LEE P
    J Immunol; 1964 Jun; 92():854-7. PubMed ID: 14210790
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.